BRPI0809677A2 - Anticorpos anti-ige - Google Patents

Anticorpos anti-ige

Info

Publication number: BRPI0809677A2
Authority: BR; Brazil
Prior art keywords: gse; antibodies; gse antibodies
Prior art date: 2007-04-02

Application number

BRPI0809677-5A2A

Other languages

English (en)

Inventor

Wai Liu

Mike Yeadon

Isabelle De Mendez

Alison Logan

Gerald F Casperson

Arvind Rajpal

Mark A Moffat

Wei Liao

Caroline Brown

Nurten Beyaz-Kavuncu

Judith Diaz-Collier

Sirid-Aimee Kellermann

Original Assignee

Pfizer

Amgen Fremont Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-02

Filing date

2008-04-01

Publication date

2014-10-07

2008-04-01 Application filed by Pfizer, Amgen Fremont Inc filed Critical Pfizer

2014-10-07 Publication of BRPI0809677A2 publication Critical patent/BRPI0809677A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Dermatology (AREA)
Mycology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

BRPI0809677-5A2A 2007-04-02 2008-04-01 Anticorpos anti-ige BRPI0809677A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US92154607P	2007-04-02	2007-04-02
US875507P	2007-12-20	2007-12-20
PCT/US2008/004286 WO2008123999A2 (en)	2007-04-02	2008-04-01	Anti-ige antibodies

Publications (1)

Publication Number	Publication Date
BRPI0809677A2 true BRPI0809677A2 (pt)	2014-10-07

Family

ID=39831518

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0809677-5A2A BRPI0809677A2 (pt)	2007-04-02	2008-04-01	Anticorpos anti-ige

Country Status (21)

Country	Link
US (2)	US7867494B2 (pt)
EP (1)	EP2142214A4 (pt)
JP (1)	JP2010532158A (pt)
KR (1)	KR20100018499A (pt)
CN (1)	CN101808661A (pt)
AR (1)	AR065921A1 (pt)
AU (1)	AU2008236765A1 (pt)
BR (1)	BRPI0809677A2 (pt)
CA (1)	CA2682927A1 (pt)
CL (1)	CL2008000935A1 (pt)
DO (1)	DOP2008000018A (pt)
GT (1)	GT200800034A (pt)
IL (1)	IL201156A0 (pt)
MX (1)	MX2009010765A (pt)
PA (1)	PA8775101A1 (pt)
PE (1)	PE20081899A1 (pt)
RU (1)	RU2009140313A (pt)
SG (1)	SG182985A1 (pt)
TW (1)	TW200904470A (pt)
UY (1)	UY30994A1 (pt)
WO (1)	WO2008123999A2 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5389442B2 (ja)	2005-09-29	2014-01-15	メディミューン，エルエルシー	膜Ｉｇ特異的抗体を同定する方法および免疫グロブリンを生成する前駆体細胞を標的化するための使用
PT2853545T (pt) *	2008-09-17	2016-08-26	Xencor Inc	Anticorpo específico para ige
PE20110891A1 (es)	2008-12-09	2011-12-23	Pfizer Vaccines Llc	Vacuna de peptido ch3 de ige
KR20110139292A (ko) *	2009-04-20	2011-12-28	화이자 인코포레이티드	단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법
US9187568B2 (en)	2009-05-07	2015-11-17	Stallergenes S.A.	Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
EP2575868A1 (en)	2010-06-07	2013-04-10	Pfizer Vaccines LLC	Ige ch3 peptide vaccine
US10017762B2 (en) *	2010-11-24	2018-07-10	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Compositions and methods for treating or preventing lupus
ES2666550T3 (es)	2011-04-19	2018-05-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos
AU2013200903B2 (en) *	2012-02-08	2015-05-14	Mcure Biosciences Inc.	CDIM binding proteins and uses thereof
WO2013119419A1 (en) *	2012-02-08	2013-08-15	North Carolina State University	Treatment of allergic diseases with recombinant antibodies
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
WO2014144817A2 (en)	2013-03-15	2014-09-18	Amgen Inc.	Inhibitory polypeptides specific to wnt inhibitors
EP3041863A4 (en)	2013-09-05	2017-08-16	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3143404B1 (en)	2014-05-16	2018-08-29	Amgen Inc.	Assay for detecting th1 and th2 cell populations
JP6519913B2 (ja) *	2015-02-05	2019-05-29	国立大学法人名古屋大学	ＩｇＥ結合性エピトープペプチドの利用
WO2016164920A1 (en)	2015-04-09	2016-10-13	Cornell University	Gene therapy to prevent reactions to allergens
WO2016191246A2 (en) *	2015-05-22	2016-12-01	Memorial Sloan-Kettering Cancer Center	T cell receptor-like antibodies specific for a prame peptide
GB201610198D0 (en) *	2016-06-10	2016-07-27	Ucb Biopharma Sprl	Anti-ige antibodies
CN107686521B (zh) *	2016-08-04	2021-04-06	越海百奥药业(绍兴)有限公司	一种人源化抗IgE单克隆抗体
WO2018089335A1 (en)	2016-11-09	2018-05-17	North Carolina State University	Treatment of allergic diseases with chimeric protein
JP7128191B2 (ja) *	2017-01-06	2022-08-30	ザリージェンツオブザユニバーシティオブカリフォルニア	治療抗ＩｇＥ抗体並びにその方法及び組成物
US12503700B2 (en)	2017-03-14	2025-12-23	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
WO2019183437A1 (en)	2018-03-23	2019-09-26	North Carolina State University	Methods and compositions for antibody to high affinity receptor for ige
US12325737B2 (en)	2018-03-26	2025-06-10	Amgen Inc.	Total afucosylated glycoforms of antibodies produced in cell culture
CN114450593A (zh)	2019-09-26	2022-05-06	美国安进公司	产生抗体组合物的方法
KR20220091567A (ko)	2019-11-01	2022-06-30	마젠타 테라퓨틱스 인코포레이티드	항-cd45 항체 및 이의 컨쥬게이트
CN113372450A (zh) *	2020-03-10	2021-09-10	北京万华生物工程有限公司	IgE嵌合性双特异性抗体制备及应用
US20230273126A1 (en)	2020-06-04	2023-08-31	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
CA3185718A1 (en) *	2020-06-15	2021-12-23	Novartis Ag	Treatment of food allergy using anti-ige antibodies
JP2023548767A (ja)	2020-10-15	2023-11-21	アムジエン・インコーポレーテツド	抗体製造方法における相対不対グリカン
KR102545843B1 (ko) *	2021-02-24	2023-06-20	주식회사 세바바이오텍	알러지, 아토피 및 가려움 개선용 기능성 소재의 스크리닝 방법
US12467094B2 (en)	2021-03-11	2025-11-11	IgGenix, Inc.	Methods and systems for predicting allergic response
EP4352094A1 (en)	2021-06-07	2024-04-17	Amgen Inc.	Using fucosidase to control afucosylation level of glycosylated proteins
US20250076309A1 (en)	2021-10-05	2025-03-06	Amgen Inc.	Fc-gamma receptor ii binding and glycan content
CN114504644B (zh) *	2021-12-24	2024-02-13	北京大学第一医院	抗IgE抗体在用于治疗腺样体肥大中的应用
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
AU2024256160A1 (en)	2023-04-20	2025-10-02	Amgen Inc.	Methods of determining relative unpaired glycan content
WO2025038600A1 (en)	2023-08-14	2025-02-20	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5449760A (en) *	1987-12-31	1995-09-12	Tanox Biosystems, Inc.	Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US6075181A (en) *	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
DK0463151T3 (da) *	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US6150584A (en) *	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6673986B1 (en) *	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ATE185601T1 (de)	1990-07-10	1999-10-15	Cambridge Antibody Tech	Verfahren zur herstellung von spezifischen bindungspaargliedern
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK1279731T3 (da)	1991-03-01	2007-09-24	Dyax Corp	Fremgangsmåde til udvikling af bindende miniproteiner
WO1992017207A1 (en) *	1991-03-26	1992-10-15	Tanox Biosystems, Inc.	MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
ATE269401T1 (de)	1991-04-10	2004-07-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1992021031A1 (en) *	1991-05-10	1992-11-26	Alain De Weck	PROCEDURE FOR DETECTING AND PREPARING ANTI-IgE AUTOANTIBODIES AND USE OF THESE ANTIBODIES AS ACTIVE AGENTS IN DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
US6699472B2 (en) *	1991-08-14	2004-03-02	Genentech, Inc.	Method of treating allergic disorders
WO1993006213A1 (en)	1991-09-23	1993-04-01	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
EP0651819A1 (en) *	1992-03-20	1995-05-10	Immunet	Methods for human monoclonal antibody production
EP0652950B1 (en)	1992-07-24	2007-12-19	Amgen Fremont Inc.	Generation of xenogeneic antibodies
US5958708A (en) *	1992-09-25	1999-09-28	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
US6130364A (en) *	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) *	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
CA2218489A1 (en) *	1995-04-21	1996-10-24	Aya Jakobovits	Generation of large genomic dna deletions
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5714352A (en) *	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
US5994619A (en) *	1996-04-01	1999-11-30	University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus	Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en) *	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
CA2273194C (en)	1996-12-03	2011-02-01	Abgenix, Inc.	Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
ATE319745T1 (de)	1997-05-21	2006-03-15	Biovation Ltd	Verfahren zur herstellung von nicht-immunogenen proteinen
US6172213B1 (en) *	1997-07-02	2001-01-09	Genentech, Inc.	Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) *	1997-07-02	1999-11-30	Genentech, Inc.	Anti-IgE antibodies and methods of improving polypeptides
KR20010034554A (ko)	1998-03-03	2001-04-25	레이몬드, 엠. 위티	치료제로서의 ｃｄ147 결합 분자
US20020029391A1 (en)	1998-04-15	2002-03-07	Claude Geoffrey Davis	Epitope-driven human antibody production and gene expression profiling
AU770555B2 (en)	1998-08-17	2004-02-26	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
CA2342967A1 (en)	1998-12-08	2000-06-15	Biovation Limited	Modifying protein immunogenicity
CA2356215C (en)	1998-12-23	2015-11-24	Pfizer Inc.	Human monoclonal antibodies to ctla-4
AU778551B2 (en) *	2000-01-14	2004-12-09	Daiichi Pharmaceutical Co., Ltd.	Novel peptide and screening method by using the same
CA2467633C (en)	2001-12-03	2012-03-27	Abgenix, Inc.	Antibody categorization based on binding characteristics
US20050169909A1 (en) *	2004-02-02	2005-08-04	Sanjaya Singh	Identification of novel IgE epitopes
CN101517068B (zh) *	2005-09-07	2017-02-08	安进弗里蒙特公司	活化素受体样激酶‑1的人单克隆抗体

2008
- 2008-04-01 TW TW097111898A patent/TW200904470A/zh unknown
- 2008-04-01 UY UY30994A patent/UY30994A1/es unknown
- 2008-04-01 AR ARP080101376A patent/AR065921A1/es not_active Application Discontinuation
- 2008-04-01 PE PE2008000595A patent/PE20081899A1/es not_active Application Discontinuation
- 2008-04-01 CA CA002682927A patent/CA2682927A1/en not_active Abandoned
- 2008-04-01 PA PA20088775101A patent/PA8775101A1/es unknown
- 2008-04-01 DO DO2008000018A patent/DOP2008000018A/es unknown
- 2008-04-01 AU AU2008236765A patent/AU2008236765A1/en not_active Abandoned
- 2008-04-01 WO PCT/US2008/004286 patent/WO2008123999A2/en not_active Ceased
- 2008-04-01 CN CN200880010487A patent/CN101808661A/zh active Pending
- 2008-04-01 KR KR1020097022898A patent/KR20100018499A/ko not_active Withdrawn
- 2008-04-01 SG SG2012048765A patent/SG182985A1/en unknown
- 2008-04-01 JP JP2010502126A patent/JP2010532158A/ja not_active Withdrawn
- 2008-04-01 EP EP08742484A patent/EP2142214A4/en not_active Withdrawn
- 2008-04-01 BR BRPI0809677-5A2A patent/BRPI0809677A2/pt not_active IP Right Cessation
- 2008-04-01 US US12/080,419 patent/US7867494B2/en not_active Expired - Fee Related
- 2008-04-01 GT GT200800034A patent/GT200800034A/es unknown
- 2008-04-01 MX MX2009010765A patent/MX2009010765A/es not_active Application Discontinuation
- 2008-04-01 RU RU2009140313/15A patent/RU2009140313A/ru not_active Application Discontinuation
- 2008-04-01 CL CL2008000935A patent/CL2008000935A1/es unknown
2009
- 2009-09-24 IL IL201156A patent/IL201156A0/en unknown
2010
- 2010-11-24 US US12/954,196 patent/US20110064726A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PA8775101A1 (es)	2008-11-19
US7867494B2 (en)	2011-01-11
CL2008000935A1 (es)	2008-11-07
SG182985A1 (en)	2012-08-30
KR20100018499A (ko)	2010-02-17
EP2142214A4 (en)	2012-03-21
WO2008123999A2 (en)	2008-10-16
US20110064726A1 (en)	2011-03-17
EP2142214A2 (en)	2010-01-13
AR065921A1 (es)	2009-07-08
PE20081899A1 (es)	2009-01-26
JP2010532158A (ja)	2010-10-07
AU2008236765A1 (en)	2008-10-16
US20090117124A1 (en)	2009-05-07
UY30994A1 (es)	2008-11-28
WO2008123999A9 (en)	2009-12-10
GT200800034A (es)	2010-03-16
WO2008123999A3 (en)	2010-06-24
MX2009010765A (es)	2009-10-26
IL201156A0 (en)	2010-05-17
DOP2008000018A (es)	2008-10-15
CN101808661A (zh)	2010-08-18
TW200904470A (en)	2009-02-01
RU2009140313A (ru)	2011-05-10
CA2682927A1 (en)	2008-10-16

Publication	Publication Date	Title
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0809677A2 (pt)	2014-10-07	Anticorpos anti-ige
CY2021027I2 (el)	2021-12-31	Σκευασματα αντισωματων anti-cd20
PL3059246T3 (pl)	2018-11-30	Zmodyfikowany region stały przeciwciała
BRPI0819165A2 (pt)	2015-06-23	Anticorpos anti-vegf
IL212175B (en)	2019-08-29	Muc1* antibodies
DK2131860T3 (da)	2014-01-13	Anti-sclerostin-antistoffer
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
PT2195026E (pt)	2014-03-31	Anticorpos anti-esclerostina
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
EP2211903A4 (en)	2011-07-06	CLL-1 ANTIBODY
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
BRPI0820073A2 (pt)	2015-06-23	Anticorpos anti-axl
BRPI0907532A2 (pt)	2015-07-28	Anticorpos anti-c5ar humanizados
BRPI0821777A2 (pt)	2015-06-16	Anticorpos biespecíficos bivalentes
PT2376116E (pt)	2016-02-24	Anticorpos anti-igf
HRP20150176T1 (xx)	2015-03-27	Protutijela protiv miostatina
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
DK2234600T3 (da)	2014-09-08	Antistofformulering
NO344963B1 (no)	2020-08-03	Humanisert antistoff
DK2059533T3 (da)	2013-02-25	Multispecifikke antistoffer
FI20075278A0 (fi)	2007-04-20	Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
EP2172483A4 (en)	2010-08-04	ANTI-MUC17 ANTIBODY
DK3118221T3 (da)	2019-09-23	Proteiner

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A E 7A ANUIDADES.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.